3 Predictions for Post-COVID Clinical Trial Decentralization
Marc Leighton, VP of Product at Florence Healthcare Prior to COVID, major technological transformation initiatives were already underway at many clinical trial sites, sponsors, and contract research organizations (CROs.) But the move to decentralized trials accelerated dramatically in 2020 and 2021–and it’s not slowing down. Survey data from WCG Avoca shows that research sites and sponsors expect 89% of clinical trials to qualify as a hybrid, with a mix of decentralized technology and in-person visits. But what will these decentralized clinical trials (DCTs) look like? I’d like to share some bold predictions for DCTs in 2022 (and beyond!): Sites and sponsors shouldn’t be locked into a zero-sum game against one another. In 2022, they’ll be unified by complementary technology and the common purpose of getting cures to market. By the end of the year, I expect the majority of sites will have an electronic Investigator Site File (eISF) and electronic informed consent (eConsent)....